GERN
Geron Corp
$1.49
+0.05 (+3.47%)
At close · Jul 7
Market Cap
$955.87M
Shares
641,520,974
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.49
Open$1.44
Day$1.41–1.50
52W$1.04–2.01
Avg vol 30d13.1M
Short int74.8M · 11.7% float · 5.9d
Short vol51%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+12%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+4%
trailing
YTD return
+13%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
8 of 255 funds reported for Jun 30 · net +654.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.67% of float · ▲ +4.3% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
255 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
−83%
Y/Y
EPS growth
+52%
Y/Y
Free cash flow
$-111.7M
Balance sheet
$77.6M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Net revenue
· 2026
Initiated
$220M – $240M
Total operating expenses
· 2026
Initiated
$230M – $240M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
8 of 255 funds reported for Jun 30 · net +654.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.67% of float · ▲ +4.3% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
255 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 46%
52-wk high $2
vs 200-day avg +7%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| demand growth quarter-over-quarter | 6% | Q1 2026 call | — |
| estimated second-line lower-risk MDS patients in the U.S. | 8,000 | Q1 2026 call | — |
| first and second-line patient starts rolling 12-month basis | 33% | rolling 12-month basis as of Q1 2026 call | — |
| gross-to-net reductions | 21% | Q1 2026 call | — |
| prescribing accounts since launch | 1,450 | since launch to Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GERN
this stock
Geron Corp
|
$955.87M | +12.9% | -82.7% | — | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GERN | +14.6% | +27.4% | +4.2% | +16.4% | +12.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +13.7% | +26.0% | -3.4% | +16.3% | +3.2% |